Design: Systematic review and meta-analysis of 11 studies
Population: 107 adults with acquired, non-cleft velopharyngeal insufficiency
Primary outcome: Improvement in speech and swallowing
Effect: Speech improved 88% (78-94%); swallowing 78% (49-93%)

A meta-analysis in The Laryngoscope (15 October 2026) pooled 11 studies of 107 adults with non-cleft, acquired velopharyngeal insufficiency, mostly after head and neck cancer treatment (45%) or from neurological disease (47%).

Injection pharyngoplasty was the commonest treatment (82% of 163 interventions), followed by palatal lift prosthesis and surgical reconstruction. Across all treatments, speech improved in 88% (95% CI 78-94%) and swallowing in 78% (49-93%). Injection pharyngoplasty had an adverse event rate of about 5%.

The evidence is small and heterogeneous, but it supports referral: adults with hypernasal speech or nasal regurgitation after cancer treatment or neurological illness often have a treatable problem.

Ask about hypernasal speech and nasal regurgitation after palate or pharynx cancer treatment
Refer suspected acquired velopharyngeal insufficiency for speech assessment and nasendoscopy
Consider injection pharyngoplasty for small to moderate gaps
Involve speech and language therapy in every case

Why it matters

A disabling problem that is often accepted after cancer treatment appears to respond well to simple procedures.

The statistics, in plain English

Pooled proportions from small, uncontrolled studies: the 88% speech improvement has a fairly tight interval, but the swallowing estimate (49-93%) is very uncertain. Without comparison groups, some improvement may reflect natural recovery.